CA9

Carbonic anhydrase 9 · Q16790 · CA9 on Sugi Atlas →

993,945 patent compounds predicted against CA9, 525,958 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sulfanilamide (SCHEMBL740)	1.00	16/20
Benzenesulfonamide (SCHEMBL729)	1.00	15/20
Busulfan (SCHEMBL4373)	0.50	15/20
Probenecid (SCHEMBL3663)	1.00	14/20
Improsulfan (SCHEMBL8954)	0.35	14/20
SCHEMBL17986	1.00	13/20
SCHEMBL3354	0.67	13/20
Formaldehyde (SCHEMBL17765)	0.52	13/20
SCHEMBL7369	0.56	12/20
Coumarin (SCHEMBL6252)	1.00	11/20
P-Toluenesulfonamide (SCHEMBL7370)	1.00	10/20
SCHEMBL19256	0.35	9/20
SCHEMBL19257	0.35	9/20
SCHEMBL3353	0.61	8/20
Sodium Lauryl Sulfate (SCHEMBL1102)	0.59	8/20
Ether (SCHEMBL15283)	0.52	8/20
SCHEMBL16817	0.51	8/20
Sulfuric Acid (SCHEMBL15284)	0.50	8/20
Sulfuric Acid (SCHEMBL15285)	0.50	8/20
Acesulfame (SCHEMBL3551)	1.00	7/20

Clinical trials — most relevant to CA9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer	PHASE3	RECRUITING
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma	PHASE2/PHASE3	COMPLETED
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies	PHASE2	WITHDRAWN
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy	PHASE2	RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer	PHASE2	RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model	PHASE1/PHASE2	UNKNOWN
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	PHASE2	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine	PHASE2	COMPLETED
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Intraoperative Dual-modality Imaging in Renal Cell Carcinoma	PHASE1	UNKNOWN
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	nan	RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Assessment of CA 19-9 in Patients' With Thyroid Malignancies	nan	UNKNOWN
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers	nan	RECRUITING
Carbohydrate Antigen 19-9 in Colorectal Cancer	nan	UNKNOWN
An Exosomal miRNA-based Liquid Biopsy for ICC Detection	nan	COMPLETED
89Zr-DFO-girentuximab Expanded Access Program (EAP)	nan	NO_LONGER_AVAILABLE
Longitudinal Pancreatic Cancer Study	nan	COMPLETED
CRC Post-surgical Assessment and Recurrence Monitoring	nan	UNKNOWN
Evaluation of CEMIP in Pancreatic Cancer	nan	UNKNOWN
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer	nan	RECRUITING
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer	nan	WITHDRAWN
Cultured Circulating Tumor Cells in Prostate and Other Cancers	nan	UNKNOWN
RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)	nan	UNKNOWN
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CA9 binder may also engage these)

Protein	Name	Similarity
Q8VHB5	—	0.990	Q8VHB5 →
Q8NAG6	—	0.964	Q8NAG6 →
A8VU90	—	0.963	A8VU90 →
Q5SZI1	—	0.962	Q5SZI1 →
Q93038	—	0.962	Q93038 →
MPL	Thrombopoietin receptor	0.961	landscape →
Q08351	—	0.961	Q08351 →
Q5U4P2	—	0.961	Q5U4P2 →
A5PJC7	—	0.960	A5PJC7 →
Q3UR50	—	0.960	Q3UR50 →
P55101	—	0.960	P55101 →
Q5VTJ3	—	0.960	Q5VTJ3 →
P48283	—	0.959	P48283 →
Q07303	—	0.959	Q07303 →
P14753	—	0.959	P14753 →
Q96A99	—	0.958	Q96A99 →
Q9H3T2	—	0.958	Q9H3T2 →
O60542	—	0.958	O60542 →
Q9HBX8	—	0.958	Q9HBX8 →
Q13477	—	0.958	Q13477 →
Q8NCW0	—	0.957	Q8NCW0 →
Q9WTM3	—	0.957	Q9WTM3 →
Q61361	—	0.957	Q61361 →
O70354	—	0.957	O70354 →
Q8IV16	—	0.957	Q8IV16 →
Q96GW7	—	0.957	Q96GW7 →
A6NGR9	—	0.957	A6NGR9 →
O19131	—	0.957	O19131 →
Q28062	—	0.957	Q28062 →
Q96F46	—	0.956	Q96F46 →